AMG-228

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAMG-228
Drug Alias NameAMG-228
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionGlucocorticoid-induced tumor necrosis factor receptor-related protein inhibitors
TargetsGlucocorticoid-induced tumor necrosis factor receptor-related protein
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmgen Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A